What's Happening?
ABK Biomedical, Inc. and COR Development have announced a partnership to establish a GMP manufacturing facility in Ashland, Missouri. This facility will focus on the production of Eye90 microspheres, a breakthrough technology for liver cancer treatment.
The project, located in Cartwright Business Park, will be managed by Coil Construction and is strategically positioned near the University of Missouri Research Reactor, which supplies the necessary yttrium-90 radioisotope. This proximity ensures a seamless supply chain for the production of Eye90 microspheres.
Why It's Important?
The establishment of this manufacturing facility is a significant development for the biotechnology and medical device industries. It represents a major investment in the production of innovative cancer treatment technologies, potentially improving patient outcomes. The facility is expected to create high-tech jobs in the Columbia area, contributing to local economic growth. Additionally, the strategic location near a key supplier of radioisotopes highlights the importance of efficient supply chain management in the production of medical devices.
What's Next?
As the facility becomes operational, it will play a crucial role in the commercialization of Eye90 microspheres. The project is expected to enhance Missouri's reputation as a hub for nuclear medicine and biotechnology. The partnership between ABK Biomedical and COR Development may lead to further collaborations and innovations in the field of medical device manufacturing.
